Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...

Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Novo Nordisk CFO Karsten Munk Knudsen tells Yahoo Finance the company understands the pressure it is under to deliver better ...

Novo Nordisk’s outgoing CEO, Lars Fruergaard Jorgensen, has warned that layoffs at the Danish pharmaceutical giant could be ...

Novo Nordisk ( NVO -4.02%) stock imitated the company's leading product on Wednesday by slimming down in price. The Danish pharmaceutical's shares lost nearly 4% of their value following its latest ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Novo Nordisk faces a critical phase with its obesity drug Wegovy as it confronts competition from Eli Lilly and potential job ...

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the ...

Novo Nordisk, the Danish drugmaker behind the popular obesity drug Wegovy, warns of fierce competition and market pressures, potentially leading to layoffs. As compounders produce cheaper copycats, U.